secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0000899923-24-000027
Event type: litigation
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics settles shareholder derivative suit; pays up to $950k in fees, adopts governance reforms
--------------------------------------------------------------------------------

- Settlement resolves claims that officers misled investors about GeneSight efficacy and study compliance.
- Myriad will adopt new disclosure committee charter, CCO job profiles, and amendments to several board committee charters.
- Plaintiffs' counsel may seek up to $950,000 in attorneys' fees and costs, paid by Myriad or its insurers.
- Court hearing on proposed settlement scheduled for August 6, 2024; defendants deny wrongdoing.
- Governance reforms to remain in effect for at least four years from adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000027/0000899923-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000027/mygn-20240603.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer